The open-source model has turned software production on its head; the decentralized, collaborative process in which anyone can look at, modify, or improve the “source code” of a computer program, provided they agree to share their modifications under the same terms, has resulted in some impressive software–Linux being the best-known example. Now biomedical researchers are beginning to question whether a similar approach could benefit drug development, according to The Economist.
At this week’s BIO 2004, a major biotech industry conference, Stephen Maurer, Arti Rai and Andrej Sali–two lawyers and a computational biologist–presented a paper calling for an open-source approach to invent drugs to fight tropical diseases. The group’s Tropical Disease Initiative would have researchers volunteer their expertise, collaborate on experiments, and post all data openly, much as happened in the Human Genome Project. However, while researchers would self-organize the direction of studies, much as happens on open-source software projects, drug development is a far more expensive undertaking than software development. The authors acknowledge that government or other major funding would be necessary to get the project going. In addition, any drug to come out of the project would go in the public domain, for generic manufacturers to produce, ensuring its availability to the most people at the lowest cost.
The idea is catching on in the biomedical research community; several other groups have adopted similar strategies. Experts see two area that could particularly benefit: discovering new applications for non-patentable compounds and drugs whose patents have expired, and developing treatments for diseases that afflict small numbers of people, such as Parkinson’s disease, or are found mainly in poor countries, such as malaria. Open source may be an idea whose time has come, for more than just computer geeks.
The big new idea for making self-driving cars that can go anywhere
The mainstream approach to driverless cars is slow and difficult. These startups think going all-in on AI will get there faster.
Inside Charm Industrial’s big bet on corn stalks for carbon removal
The startup used plant matter and bio-oil to sequester thousands of tons of carbon. The question now is how reliable, scalable, and economical this approach will prove.
The dark secret behind those cute AI-generated animal images
Google Brain has revealed its own image-making AI, called Imagen. But don't expect to see anything that isn't wholesome.
The hype around DeepMind’s new AI model misses what’s actually cool about it
Some worry that the chatter about these tools is doing the whole field a disservice.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.